Introduction Many immunomodulators have been studied in clinical trials for the treatment of
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …

Japanese encephalitis (JE) remains the cause of vaccine-preventable encephalitis in
individuals living in endemic areas and international travelers. Although rare, the disease’s high …

Introduction Expatriates working in low-and middle-income countries have unique health
problems. Migration leads not only to an increase in individual health risk but also a risk of …

Polymyxin B remains the last-line treatment option for multidrug-resistant Gram-negative
bacterial infections. Current US Food and Drug Administration-approved prescribing …

Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …

Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …

Background and Aim Cholangiocarcinoma patients usually have poor treatment outcome
and a high mortality rate. The role of adjuvant chemotherapy (AC) is controversial. Our study …

Dengue infection has been a public health problem worldwide, especially in tropical areas.
A lack of sensitive diagnostic methods in the early phase of the illness is one of the …